Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that Stephen Hurly, CEO, will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 8:40 a.m. ET. This virtual event will provide insights into the company's bispecific gamma delta T cell engagers developed using its Gammabody™ platform. The company is currently enrolling patients for its Phase 1/2a clinical studies for LAVA-051 and LAVA-1207, targeting hematological malignancies and prostate cancer, respectively. Topline data from these studies is anticipated in 2022.
- LAVA Therapeutics is actively recruiting for Phase 1/2a clinical studies for both LAVA-051 and LAVA-1207, showing progress in their drug development pipeline.
- Topline clinical data from the Phase 1 dose escalation phase of LAVA-051 is expected in the first half of 2022, potentially indicating significant advancement in their research.
- None.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference is being conducted in a virtual format and the presentation will take place on Thursday, Feb. 17, 2022 at 8:40 a.m. ET.
Access to the recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector functions upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematological malignancies is currently enrolling (NCT04887259). The company currently anticipates data from the Phase 1 dose escalation phase of the study in the first half of 2022 with top line clinical data from the Phase 2a expansion cohorts expected in the second half of 2022. The company is actively recruiting patients in a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer. For more information, please visit www.lavatherapeutics.com and follow us on LinkedIn, Twitter and YouTube.
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our GammabodyTM platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
CONTACT
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com
Catherine Day
+1-917-763-2709
catherine@newdaybioconsulting.com
FAQ
When is the LAVA Therapeutics presentation at the 11th Annual Global Healthcare Conference?
What is the focus of LAVA Therapeutics' Gammabody™ platform?
What clinical studies is LAVA Therapeutics currently conducting?
What timeline is expected for clinical data from LAVA Therapeutics' studies?
